Johnson & Johnson's quick reaction last week to potentially damaging news about the safety of its painkiller Tylenol furthered the company's reputation for savvy crisis management. But the going is likely to get tougher in the months ahead.Experts say J&J will have to walk a fine line between reassuring the public that its pills are safe without overstating its case and stirring up criticism.
On July 3, just three days after a Food and Drug Administration advisory panel recommended sweeping limits on acetaminophen, the generic name for Tylenol and some of its rivals, J&J ran full-page ads in USA ...
Hola Fernando Comas.
ResponderEliminarTe saludo desde Zaragoza,soy una limeña afincada en esta ciudad hace aprox.20 años.Me alegra y satisface ver la labor que estas realizando siempre fuiste una persona muy dinámica y con mucha fuerza , veo que lo sigues siendo.
Mi enhorabuena.
Un abrazo. Gloria M.J.
Gracias por entrar Gloria. Gracias por tus comentarios.
ResponderEliminarEscribeme a mi correo y/o dejame tu dirección.
Gracias